In this study, we have presented preclinical evidence, in proof of concept, that targeting FBXL2/Grp94 to facilitate EGFR protein turnover may be a new therapeutic strategy for the treatment of TKI-resistant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.